Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibTerminated
NCT06754761Phase 1Updated Sep 3, 2026
Sponsor: AstraZeneca
Neoplasm
United Kingdom
Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemRecruiting
NCT07361276N/AUpdated Sep 3, 2026
Sponsor: AstraZeneca
Hypertension
Brazil
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruiting
NCT07427394Phase 2Updated Sep 3, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, United Kingdom
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)Completed
NCT04136171Phase 3Updated Sep 3, 2026
Sponsor: Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
United States, Argentina, Australia, Austria, Belgium +16 more
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active Not Recruiting
NCT04035486Phase 3Updated Sep 3, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Brazil, Canada +16 more
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive Not Recruiting
NCT04699838Phase 2Updated Sep 3, 2026
Sponsor: Muhammad Furqan
Extensive Stage Small Cell Lung Cancer
United States
CHARM Hepatocellular Carcinoma MEA StudyRecruiting
NCT07650773N/AUpdated Sep 3, 2026
Sponsor: AstraZeneca
HepatoCellular Carcinoma
Egypt, Kuwait, Morocco, Qatar, Saudi Arabia +2 more
Study of Patient With Frequent Exacerbations in MoscowRecruiting
NCT07307781N/AUpdated Sep 3, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Russia
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Recruiting
NCT07357597Phase 4Updated Sep 3, 2026
Sponsor: AstraZeneca
Stomatitis
United States
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Recruiting
NCT06878261Phase 3Updated Sep 3, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Australia, Belgium, Bulgaria +17 more
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)Recruiting
NCT06883305Phase 3Updated Sep 3, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Brazil, Canada, Chile, China +13 more
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive Not Recruiting
NCT05374603Phase 2Updated Sep 3, 2026
Sponsor: AstraZeneca
Lung Cancer
China
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerRecruiting
NCT07192614Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: AstraZeneca
Prostate Cancer
United States, Belgium, Canada, China, Japan +4 more
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibActive Not Recruiting
NCT06899061Phase 1Updated Sep 2, 2026
Sponsor: AstraZeneca
Advanced Solid Malignancies
Bulgaria, Moldova, Romania
A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical PracticeNot Yet Recruiting
NCT07800754N/AUpdated Sep 2, 2026
Sponsor: AstraZeneca
Gastric Cancer · Gastroesophageal Junction Cancer
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of HistologyRecruiting
NCT07167433N/AUpdated Sep 2, 2026
Sponsor: AstraZeneca
Ovarian Cancer
Brazil
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceRecruiting
NCT06995833N/AUpdated Sep 2, 2026
Sponsor: AstraZeneca
Endometrial Cancer
South Korea
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLCRecruiting
NCT07413757N/AUpdated Sep 2, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
China
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementRecruiting
NCT06728410Phase 2Updated Sep 2, 2026
Sponsor: Mehmet Akce
Intrahepatic Cholangiocarcinoma · FGFR2 Gene Rearrangement · FGFR2 Gene Mutation
United States
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaActive Not Recruiting
NCT06942910Phase 2Updated Sep 2, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease With High Proteinuria
Russia
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive Not Recruiting
NCT05057494Phase 3Updated Sep 2, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
United States, Australia, Czechia, France, Hungary +2 more
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot Yet Recruiting
NCT06855225Phase 2Updated Sep 2, 2026
Sponsor: Mehmet Akce
Combined Hepatocellular and Cholangiocarcinoma
United States
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersRecruiting
NCT06659029N/AUpdated Sep 2, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruiting
NCT06380751Phase 3Updated Sep 2, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, Argentina, Australia, Austria, Brazil +24 more
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive Not Recruiting
NCT05951959Phase 2Updated Sep 2, 2026
Sponsor: AstraZeneca
Mantle Cell Lymphoma (MCL)
United States, Australia, Brazil, Canada, Poland +2 more

Previous page Next page